Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01355458 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Phase 3 study of Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
- 15
- Study locations
NCT01355458 is a Phase 3 study of Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 260 participants, above the 232-participant average among 23 other Rosacea trials with a reported enrollment target (12% higher). The trial reports 15 study locations across 11 states.
The verdict
NCT01355458, a Phase 3 study of Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
- 15
- Study locations
Study Summary
Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CD07805/47 gel
Study Locations (15)
Texas
- Arlington Center for Dermatology - Arlington
- DermResearch, Inc. - Austin
- Dermatology Treatment & Research Center - Dallas
California
- Dermatology Research Associates - Los Angeles
- University of California, San Francisco - San Francisco
Ontario
- Lynderm Research Inc - Markham
- Windsor Clinical Research Inc. - Windsor
Michigan
- Michigan Center for Skin Care Research - Clinton Township
New Jersey
- Windsor Dermatology - East Windsor
North Carolina
- Dermatology Consulting Services - High Point
Oregon
- Oregon Medical Research Center - Portland
Pennsylvania
- Philadelphia Institute of Dermatology - Fort Washington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01355458
The ClinicalTrials.gov registry entry for NCT01355458 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 232-participant average among 23 other Rosacea trials with a reported enrollment target (12% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01355458 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, Ontario.
Frequently Asked Questions
What is clinical trial NCT01355458 about?
NCT01355458 is a clinical study titled "Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea". Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythe...
What is the current status of trial NCT01355458?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2011-05. Estimated completion is 2011-12.
What conditions does trial NCT01355458 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT01355458?
The interventions under investigation include: Placebo (DRUG), CD07805/47 gel (DRUG).
Who is sponsoring clinical trial NCT01355458?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01355458 being conducted?
This trial has 15 study locations across California, Michigan, New Jersey, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
COMPLETED · Phase 3
-
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
COMPLETED · Phase 3
-
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.